Optimal dosing and triggers for prophylactic use of platelet transfusions.

Abstract

Despite the reliance on platelet transfusion support in patients receiving myeloablative therapy, controversies surround platelet transfusion practices. These include the appropriate platelet dose and the threshold at which prophylactic platelet transfusions will be most effective. These issues bear directly on patient outcome (donor exposure and bleeding complications), cost effectiveness of transfusion, and maintenance of adequate platelet inventories. This review examines the recent studies that have taken on the task of resolving these questions in order to provide optimal platelet transfusion guidelines. Studies now have convincingly demonstrated that a 10,000/microL threshold for prophylactic platelet transfusion is safe and effective in uncomplicated thrombocytopenic patients. Although platelet dosages vary, in general, smaller doses are both effective and inventory-sparing in the more complicated inpatient setting, while larger platelet doses allow for an increased transfusion interval for chronic outpatient support.